CKD患者高磷血症的最新管理:NKF-KDOQI争议视角
本文为NKF-KDOQI争议视角,讨论CKD及肾衰竭透析患者中磷结合剂使用的证据基础,聚焦不同类别磷结合剂的比较。指南建议将升高的血磷降至正常范围,但临床试验未明确显示任一类别磷结合剂在临床结局上的优势,且磷结合剂增加药片负担、自付费用和副作用,导致使用选择存在不确定性。
要点
- CKD G3a及以上患者指南建议降磷至正常范围,可选饮食限磷或磷结合剂。
- 临床试验未证实任一类别磷结合剂在临床结局上优于另一类。
- 磷结合剂增加药片负担、自付费用且多有副作用,选择存在不确定性。
核心结论
- 磷结合剂在CKD和肾衰竭患者中的使用及最佳选择存在不确定性,因缺乏临床结局优势证据且负担显著。
研究设计与样本
- NKF-KDOQI争议视角文章,基于现有证据讨论CKD和肾衰竭中磷结合剂使用及类别比较。
主要发现
- 临床试验未明确显示任一类别磷结合剂在临床结局上优于另一类。
- 磷结合剂显著增加患者药片负担和自付费用,且许多有副作用。
关键数值与推荐
- CKD G3a及以上(含透析肾衰竭)指南建议将升高的血磷降至正常范围,策略包括饮食限磷或使用磷结合剂。
- 指南建议限制口服元素钙(常含于磷结合剂)的使用。
- CKD营养指南建议每日钙摄入<800-1,000mg;CKD骨矿物质 disorder指南未提供明确目标,但既往推荐维持性透析患者<1,500mg。
临床怎么用
- 临床需权衡磷结合剂的获益与药片负担、费用及副作用,个体化选择。
- 关注口服元素钙摄入,参考营养指南钙摄入建议。
局限性
- 文章为争议视角,非系统综述或meta分析,未提供新的试验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phosphate binders are among the most common medications prescribed to patients with kidney failure receiving dialysis and are often used in advanced chronic kidney disease (CKD). In patients with CKD glomerular filtration rate category 3a (G3a) or worse, including those with kidney failure who are receiving dialysis, clinical practice guidelines suggest "lowering elevated phosphate levels towards the normal range" with possible strategies including dietary phosphate restriction or use of binders. Additionally, guidelines suggest restricting the use of oral elemental calcium often contained in phosphate binders. Nutrition guidelines in CKD suggest<800-1,000mg of calcium daily, whereas CKD bone and mineral disorder guidelines do not provide clear targets, but<1,500mg in maintenance dialysis patients has been previously recommended. Many different classes of phosphate binders are now available and clinical trials have not definitively demonstrated the superiority of any class of phosphate binders over another with regard to clinical outcomes. Use of phosphate binders contributes substantially to patients' pill burden and out-of-pocket costs, and many have side effects. This has led to uncertainty regarding the use and best choice of phosphate binders for patients with CKD or kidney failure. In this controversies perspective, we discuss the evidence base around binder use in CKD and kidney failure with a focus on comparisons of available binders.
引用
- Scialla JJ, Kendrick J, Uribarri J, et al. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective. Am J Kidney Dis. 2020. PMID: 32771650. doi:10.1053/j.ajkd.2020.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。